Cataplexy and monoamine oxidase deficiency in Norrie disease

Norrie disease (ND) is an X-linked recessive disorder causing ocular atrophy, mental retardation, deafness, and dysmorphic features. Virtually absent monoamine oxidase (MAO) type-A and -B activity has been found in some boys with chromosome deletions. We report the coexistence of cataplexy and abnormal REM sleep organization with ND. Three related boys, referred for treatment of medically refractory atonic spells and apneas, underwent extended EEG-video-polysomnographic monitoring. They demonstrated attacks of cataplexy and inappropriate periods of REM sleep during which they were unarousable. One boy also had generalized tonic-clonic seizures. Previous testing revealed that all three have complete ND gene deletions. In all subjects, platelet MAO-B activity was absent, serum serotonin levels were markedly increased, and plasma catecholamine levels were normal. Data from the canine narcolepsy syndrome model implicate abnormal catecholaminergic and cholinergic activities in the pathogenesis of cataplexy. Our findings suggest that abnormal MA0 activity or an imbalance between serotonin and other neurotransmitter levels may be involved in the pathogenesis of human cataplexy.

[1]  E. Mignot,et al.  Effect of 5-HT1A receptor agonists and antagonists on canine cataplexy. , 1995, The Journal of pharmacology and experimental therapeutics.

[2]  Clarke Kh Strategies for increasing nursing involvement in facility planning. , 1995 .

[3]  D. Vossler Nonepileptic seizures of physiologic origin , 1995 .

[4]  K. Werdan,et al.  Bidirectional effects of endogenous opioid peptides on endothelin release rates in porcine aortic endothelial cell culture: mediation by delta opioid receptor and opioid receptor antagonist-insensitive mechanisms. , 1995, The Journal of pharmacology and experimental therapeutics.

[5]  E. Mignot,et al.  Neuropharmacology and neurochemistry of canine narcolepsy. , 1994, Sleep.

[6]  Xini Zhang,et al.  Effects of Gestational Exposure to Monoamine Oxidase Inhibitors in Rats: Preliminary Behavioral and Neurochemical Studies , 1994, Neuropsychopharmacology.

[7]  Borrie Wd Progress in Australian demography. , 1994 .

[8]  M. Goldberg,et al.  Identification of a nonsense mutation at codon 128 of the Norrie's disease gene in a male infant. , 1993, Archives of ophthalmology.

[9]  C. Guilleminault,et al.  Further characterization of the alpha-1 receptor subtype involved in the control of cataplexy in canine narcolepsy. , 1993, The Journal of pharmacology and experimental therapeutics.

[10]  P. N. Rao,et al.  Inversion (X)(p11.4q22) associated with Norrie disease in a four generation family. , 1993, American journal of medical genetics.

[11]  J. Montplaisir,et al.  Effects of modafinil on symptomatology of human narcolepsy. , 1993, Clinical neuropharmacology.

[12]  M. Aldrich,et al.  Autoradiographic studies of post-mortem human narcoleptic brain , 1993, Neurophysiologie Clinique/Clinical Neurophysiology.

[13]  E. Richelson,et al.  Desensitization and down-regulation of neurotensin receptors in murine neuroblastoma clone N1E-115 by [D-Lys8] neurotensin(8-13). , 1993, The Journal of pharmacology and experimental therapeutics.

[14]  B. Hirsch,et al.  Pericentric inversion of chromosome 4 giving rise to dup(4p) and dup(4q) recombinants within a single kindred. , 1993, American journal of medical genetics.

[15]  R. Cantor,et al.  Linkage analysis of Norrie disease with an X-chromosomal ornithine aminotransferase locus. , 1993, Transactions of the American Ophthalmological Society.

[16]  M. Haasemann,et al.  Norrie disease is caused by mutations in an extracellular protein resembling C–terminal globular domain of mucins , 1992, Nature Genetics.

[17]  M. Jobling,et al.  Isolation and characterization of a candidate gene for Norrie disease , 1992, Nature Genetics.

[18]  S. Kish,et al.  Brain neurotransmitter changes in human narcolepsy , 1992, Neurology.

[19]  D. Murphy,et al.  Clinical, biochemical, and neuropsychiatric evaluation of a patient with a contiguous gene syndrome due to a microdeletion Xp11.3 including the Norrie disease locus and monoamine oxidase (MAOA and MAOB) genes. , 1992, American journal of medical genetics.

[20]  M. Ludman,et al.  GMS syndrome: a new dominant condition with goniodysgenesis, mental retardation, and short stature. , 1992, American journal of medical genetics.

[21]  D. Murphy,et al.  Abnormal protein in the cerebrospinal fluid of patients with a submicroscopic X-chromosomal deletion associated with Norrie disease: preliminary report. , 1991, Applied and theoretical electrophoresis : the official journal of the International Electrophoresis Society.

[22]  A. Chapelle,et al.  Monoamine oxidase deficiency in males with an X chromosome deletion , 1989, Neuron.

[23]  C. Maggs Ethel Manson and Henry Burdett: two great minds not thinking alike. , 1989, History of nursing bulletin.

[24]  S. Sheps,et al.  Diagnostic evaluation of pheochromocytoma. , 1988, Endocrinology and metabolism clinics of North America.

[25]  A. Reiss,et al.  Determination of a reference range for whole blood serotonin in a pediatric population using high pressure liquid chromatography with electrochemical detection. , 1986, Clinical biochemistry.

[26]  G. Sweeney,et al.  Porphyria cutanea tarda, or the uroporphyrinogen decarboxylase deficiency diseases. , 1986, Clinical biochemistry.

[27]  D. Murphy,et al.  Platelet and plasma amine oxidase activity in 680 normals: Sex and age differences and stability over time , 1976 .

[28]  W. Ganado The narcolepsy syndrome. , 1958, Neurology.